将 B 细胞与浆细胞靶向从肿瘤学转化至自身免疫:模式、定量桥接与开发路线图 Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap. PubMed 2026/06/05 发表Clin Pharmacol TherQ1 · IF 4.9(JCR 2025) 靶点:CD19靶点:CD20靶点:CD38技术:双特异性抗体淋巴瘤骨髓瘤
肾脏病学趋势:从虚无主义到抗体介导排斥反应的靶向治疗 Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection. PubMed 2026/01/24 发表Nephrol Dial TransplantQ1 · IF 8.3(JCR 2025) 靶点:CD19靶点:CD20靶点:CD38技术:NK 细胞技术:双特异性抗体多发性骨髓瘤
解析 MYC 介导的对传统抗体与 T 细胞重定向治疗性抗体的逃逸机制 Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies. PubMed 2024/11/11 发表Int J Mol SciQ1 · IF 5.6(JCR 2025) 靶点:CD19靶点:CD20靶点:CD38技术:NK 细胞技术:基因编辑技术:双特异性抗体
新型 NKG2D 靶向双特异性抗体增强 NK 细胞和 T 细胞对恶性 B 细胞的抗体介导杀伤 Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells. PubMed 2023/10/27 发表Front ImmunolQ1 · IF 7(JCR 2025) 靶点:CD19靶点:CD20靶点:CD38技术:NK 细胞技术:双特异性抗体淋巴瘤
儿童、青少年及年轻成人非霍奇金淋巴瘤的细胞与体液免疫治疗 Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma. PubMed 2023/02/02 发表Best Pract Res Clin HaematolQ2 · IF 3.4(JCR 2025) 人群:儿童人群:成人靶点:CD19靶点:CD20靶点:CD22技术:CAR-NK技术:NK 细胞技术:双特异性抗体
B 细胞恶性肿瘤新型治疗药物的现状:下一步是什么? Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next? PubMed 2022/12/07 发表Cancers (Basel)Q2 · IF 4.8(JCR 2025) 靶点:CD19靶点:CD20靶点:CD22技术:双特异性抗体B细胞淋巴瘤淋巴瘤白血病